Washington, DC—The approval of once-monthly
ibandronate in March by the Food and Drug Administration (FDA) may substantially
improve patients’ ability to adhere to osteoporosis treatments. The
trend of drug companies testing osteoporosis drugs in clinical trials that
require less frequent doses was highlighted at the Sixth International Symposium
on Osteoporosis in April.
The FDA-approved drugs for the treatment of osteoporosis in postmenopausal
women include antiresorptive agents that reduce bone loss: estrogen, calcitonin,
raloxifene (a selective estrogen receptor modulator or SERM), and bisphosphonates
(alendronate, and risedronate, which are taken daily or weekly) and ibandronate
(taken monthly). For patients who do not respond to antiresorptives, there
is one FDA-approved anabolic agent, teriparatide, a synthetic form of parathyroid
hormone, which can help build bone.
Kuehn BM. Longer-lasting Osteoporosis Drugs Sought. JAMA. 2005;293(20):2458. doi:10.1001/jama.293.20.2458